Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

Nirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 000 single doses were administered in infants younger than 1 year during the 2023–24 season. In this context, the selection and spre...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet infectious diseases
Main Authors:	Reslan, Alawiya, Casalegno, Jean-Sébastien, Chollet, Lionel, Pillet, Sylvie, Tremeaux, Pauline, Salmona, Maud, Imbert-Marcille, Berthe-Marie, Larrat, Sylvie, Marot, Stéphane, Stephan, Valentin, Brichler, Ségolène, Jaffar-Bandjee, Marie-Christine, Francois, Catherine, Hartard, Cédric, Dos Santos, Georges, Simon-Loriere, Etienne, Schwartz, Olivier, Buchrieser, Julian, Pawlotsky, Jean-MiIchel, Lemoine, Frédéric, Audureau, Etienne, Rameix-Welti, Marie-Anne, Zemali, Naël, Moisan, Alice, Zavaoarisaina, Zakasoa-Mbololona, Avettand-Fenoel, Véronique, Guillaume, Clémence, Mchantaf, Gilbert, Marie, Victoria, Bret, Laurent, Lesne, Fabien, Alidjinou, Kazali, de Pontual, Loic, Aupiais, Camille, Perrier, Marine, Jatteau, Pierre, Fofana, Djeneba, Cocherie, Théophile, Soulié, Cathia, Faisant, Anne, Tournegros, Caroline, Bourlet, Thomas, Bouthry, Elise, Warnakulasuriya, Fairly, Jaffar, Marie-Christine, Heaugwane, Diana, Azemar, Benjamin, Castelain, Sandrine, Rames, Cinthia, Bécourt, Arnaud, Foulongne, Vincent, Domitien, Léa, Handala, Lynda, Gaudy-Graffin, Catherine, Crémadés, Agathe, Gabassi, Audrey, Néré, Marie-Laure, Bonacorsi, Stéphane, Ouldali, Naim, Reslan, Alawyia, Bourret, Jérome, Yab, Emilie, Enouf, Vincent, Donati, Flora, Prot, Matthieu, Jeyarajah, Banujaa, Dossou, Nefert Candace, Vabret, Astrid, Rodriguez, Christophe, Cappy, Pierre, Soulier, Alexandre, Ader, Mohamed, Natella, Pierre-André, Fagour, Laurence, Schapira, Anne-Julie, Leveque, Nicolas, Morton Fauche, Claire, Castain, Louise, Rodallec, Audreay, Gras-le Guen, Christele, Chauvire-Drouard, Anne, Deback, Claire, Solis, Morgane, Gaitan, Léa, Mirand, Audrey, Thibault, Vincent, Trémeaux, Pauline, Claudet, Isabelle, Pucelle, Mélanie, Vellas, Camille, Veyrenche, Nicolas, Gaymard, Alexandre, Kombou, Jose
Format:	Journal Article
Language:	English
Published:	United States Elsevier Ltd 14-10-2024 New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001
Subjects:	Human health and pathology Life Sciences Pulmonology and respiratory tract
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Nirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 000 single doses were administered in infants younger than 1 year during the 2023–24 season. In this context, the selection and spread of escape variants might be a concern. Here, we aimed to characterise RSV associated with breakthrough infection. We did a multicentre, national, observational study in France during the 2023–24 RSV season in RSV-infected infants (aged <1 year) who either received or did not receive a dose of nirsevimab before their first RSV season. We excluded infants with insufficient information about nirsevimab treatment or without parental consent. We used respiratory samples collected in each laboratory for full-length RSV RNA sequencing to analyse changes in the nirsevimab binding site Ø. We tested clinical RSV isolates for neutralisation by nirsevimab. We analysed F candidate substitutions by fusion-inhibition assay. Of the 695 RSV infected infants, we analysed 545 (78%) full-length RSV genome sequences: 260 (48%) from nirsevimab-treated breakthrough infections (236 [91%] RSV-A and 24 [9%] RSV-B) and 285 (52%) from untreated RSV-infected infants (236 [83%] RSV-A and 49 [17%] RSV-B). Analysis of RSV-A did not reveal any substitution in site Ø known to be associated with resistance to nirsevimab. Two (8%) of 24 RSV-B breakthrough infections had resistance-associated substitutions: F:N208D (dominant resistance-associated substitution) and a newly described F:I64M plus F:K65R combination (minority resistance-associated substitution), both of which induced high levels of resistance in the fusion-inhibition assay. This study is, to the best of our knowledge, the largest genotypic and phenotypic surveillance study of nirsevimab breakthrough infections to date. Nirsevimab breakthrough variants remain very rare despite the drug's widespread use. The detection of resistance-associated substitutions in the RSV-B F protein highlights the importance of active molecular surveillance. ANRS Maladies Infectieuses Emergentes and the French Ministry of Health and Prevention.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1473-3099 1474-4457 1474-4457
DOI:	10.1016/S1473-3099(24)00570-X